In recent years, with the help of the national "blue economy" strategy, the marine biopharmaceutical industry has become the most active and rapidly developing field in the pharmaceutical industry. At the same time, the research and development of marine biopharmaceuticals has received high attention from the government, and relevant support policies have been introduced in various regions to vigorously promote and develop the marine biopharmaceutical industry from the government level. The industrial development space is enormous.
During the 13th Five Year Plan period, as a key focus of the biological industry, marine biological innovative medicine will usher in new development opportunities. Chengyi Pharmaceutical, which successfully went public last year, is the first marine biopharmaceutical listed company in Zhejiang Province. According to Yan Yiyi, Chairman of Zhejiang Chengyi Pharmaceutical, in January of this year, the company's various business indicators increased significantly compared to the same period last year, showing a great trend.
At present, Chengyi Pharmaceutical is focusing on marine medicine, biopharmaceuticals, traditional Chinese medicine, and new formulations as its main development directions. With the advantage of landing on the main board of the Shanghai Stock Exchange, through mergers and acquisitions, shareholding and other forms, it has planned, step-by-step, actively and steadily entered the capital market, extending the industrial chain and achieving leapfrog development of the company.
1. Launch of selection of raw material drug bases
As an important supplier of raw materials in the global pharmaceutical industry, Chengyi Pharmaceutical mainly cooperates with high-end customers for exporting raw materials. The product quality is higher than national pharmacopoeia standards, and there is a higher premium compared to similar products. Multiple raw material drug products have been certified by the US FDA, UK MHRA, Australia TGA, and others. Has a high level of recognition among foreign customers.
To better continue this advantage, Chengyi Pharmaceutical has recently vigorously promoted the construction of the Xiaomenshan API production base. On February 3rd, the company held "product selection meetings" and "expert symposiums" in Shanghai and other places to inject the "Chengyi Pharmaceutical sector" into the Wenzhou Petrochemical Base at a high starting point and carry out strategic planning work such as product selection.
In January of this year, the Wenzhou Municipal Party Committee and Government held the "On site Promotion Meeting for the Cultivation of New Energy and the Transformation and Improvement of Traditional Manufacturing Industry in Wenzhou", and issued the "21 New Energy Policies", listing biopharmaceuticals as a "strategic emerging industry" in Wenzhou, with a focus on supporting its development. After a typical speech at the "on-site promotion meeting", representatives of Chengyi Pharmaceutical enterprises revealed that they will accelerate the construction of the "Chengyi Pharmaceutical Plate" base in Xiaomen Island based on the overall planning of Wenzhou City and Dongtou District, with the support of relevant provincial and municipal departments.
According to reports, Xiaomen Island is located in the northern part of Damen Island in Dongtou District, with an area of 4.62 square kilometers and a total coastline of 16.95 kilometers. Large state-owned enterprises such as China Petroleum Asphalt and Huadian Energy have been stationed for many years, making it one of the important bases for Wenzhou to cultivate "new energy". On November 9th last year, Chengyi Pharmaceutical invited relevant experts to lead an expedition to the island.
Chengyi Pharmaceutical Executive Visits Dongtou Xiaomenshan Base
At the "Selection Meeting" on February 3rd, experts from the national "Thousand Talents Plan", provincial "Thousand Talents Plan", and many scientific research institutions, such as doctoral students, requested that Dongtou District, in combination with the planning and positioning of the Xiaomen Island Port Industry Base, focus on selecting products with competitive advantages in marine biology, select and develop first generation products, and cultivate its own characteristics and advantages.
2. Accelerated preparation of expert workstations
Based on the company's development strategy and plan, Sincere Pharmaceutical has implemented optimized allocation of human resources in recent years, adhering to people-oriented principles, strengthening talent introduction and training, improving incentive mechanisms, strengthening corporate culture construction, and achieving sustainable development of the company. The author has learned that Chengyi Pharmaceutical is continuously introducing external talents and recruiting excellent professional technical and management talents from various sectors of society and major universities. Among them, the academician expert workstation is the core of the talent strategy. Yan Yiyi revealed that the company has recently visited multiple academicians of the Chinese Academy of Sciences, established academician workstations, actively selected anti-tumor drugs, and entered the research and development stage as soon as possible.
Yan Yiyi (fourth from left), Chairman of Chengyi Pharmaceutical, Visits Ocean University of China
It is understood that the close cooperation between Chengyi Pharmaceutical and the municipal and district associations for science and technology is an important driving force for the construction of academician and expert workstations. Last August, with the help of the Wenzhou Association for Science and Technology, we went to Shanghai with Chengyi Pharmaceutical to visit Academician Ding Jian from the Shanghai Institute of Pharmacy of the Chinese Academy of Sciences and Academician Hou Huimin from the Engineering Academy, together with the District Talent Office. This laid a solid foundation for the establishment of the Chengyi Pharmaceutical Academician Expert Workstation. In order to promote the progress of the workstation, under the leadership of David Wen, Vice Chairman of the Wenzhou Association for Science and Technology, the District Talent Office and the District Association for Science and Technology once again went to Shanghai with Chengyi Pharmaceutical to visit and connect with Academician Ding Jian. During this meeting, both parties had a sincere discussion on the construction of the Chengyi Pharmaceutical Academician Expert Workstation.
Ren Bingjun, General Manager of Zhejiang Chengyi Pharmaceutical Co., Ltd., represented the Chairman of the Company to report to Academician Ding on the company's recent production, operation, and talent recruitment work, and expressed the urgent desire of Academician Ding to provide forward-looking guidance, assistance, and cooperation in the upcoming layout of the over 200 acre raw material base. Academician Ding also explicitly stated that he will arrange a visit to Chengyi Pharmaceutical as soon as possible after the Spring Festival.
In addition, Ren Bingjun also visited Academician Yue Jianmin from the Shanghai Institute of Pharmacy, Chinese Academy of Sciences, and Academician Hou Huimin from the National Pharmaceutical Engineering Research Center. Both academicians stated that they would visit and inspect Dongtou at appropriate times.
Industry reviews suggest that Chengyi Pharmaceutical focuses on strengthening the introduction of technical and various management talents, strengthening the company's scientific research and technical strength and management team, optimizing the personnel structure of the enterprise, meeting the sustainable development needs of the enterprise, and promising future development.
3. Consolidate the foundation to help take off
Chengyi Pharmaceutical is committed to developing high-end small variety "marine green drugs" and "large disease drugs". In addition to analyzing the overall situation, it is more about leveraging its location advantages as an island enterprise in the future. Its flagship product, glucosamine hydrochloride, is a model among them.
It is reported that glucosamine hydrochloride can block the pathogenesis of osteoarthritis, promote the synthesis of proteoglycans with normal structures by chondrocytes, and inhibit the production of enzymes that damage tissues and cartilage (such as collagenase and phospholipase A2), reduce damage to chondrocytes, improve joint activity, alleviate joint pain, and delay the progression of osteoarthritis. The raw material of this product is prepared by hydrolysis of chitin, which is commonly extracted from crab and shrimp shells. Due to its light weight and large volume, it is not convenient for transportation. Chengyi Pharmaceutical has utilized its location advantage to become the main raw material drug manufacturer of glucosamine hydrochloride in China, and the glucosamine hydrochloride preparation ranks first in China, forming a certain advantage in the entire industry chain. In recent years, the sales of glucosamine hydrochloride in China have been increasing at an annual rate of over 20%, making it a rising variety with market potential. It is predicted that the market size of domestic glucosamine hydrochloride preparations may exceed 4.1 billion yuan by 2018.
In addition, Chengyi Pharmaceutical's recently obtained drug approval number for the biopharmaceutical Danyining tablet is also receiving industry attention. It is reported that Danyining Tablets, developed as biological and traditional Chinese medicine extracts, are mainly used for the treatment of acute and chronic cholecystitis, biliary tract infections, gallbladder and bile duct stones (including residual stones), and can be used to prevent stone recurrence. They have obvious cholagogic, stone removal, anti-inflammatory, and analgesic effects, are easy to take, have a fast onset time, and have no toxic or side effects. Their clinical efficacy is very significant.
Chengyi Pharmaceutical Holds a National Investment Promotion Conference for Danyining in Guangzhou
We have conducted a series of laboratory studies to ensure the effectiveness and safety of Danyining tablets from raw material procurement to production, "said a person from Chengyi Pharmaceutical. Currently, pharmacological experiments have proven that Danyining tablets take effect quickly and have no impact on blood pressure; The acute toxicity test confirmed that the product has no toxic side effects; Through subacute toxicity experiments, it has been confirmed that Lidan tablets have no effect on blood biochemistry and have a strong cholagogic effect. We have also conducted extensive research on the process and quality of Danyining tablets, utilizing the latest technology to ensure consistent product quality and stability. Market analysis suggests that as an exclusive traditional Chinese medicine variety in China, Danyining tablets are suitable for a large number of people with gallbladder diseases and have broad market sales prospects.
Chengyi Pharmaceutical stated that in the future, it will continue to adhere to innovation as the driving force, talent as the foundation, and market orientation, strengthen scientific research capabilities, accelerate product upgrading and upgrading, promote the transformation of product structure from raw materials to formulations, improve core competitiveness, seize opportunities, forge ahead, and strive for excellence through observation, accumulation and thin development, creating a new legend of marine medicine.